Remission of acanthosis nigricans associated with polycystic ovarian disease and a stromal luteoma.
D015068:17-Ketosteroids / Q000652:urine; D000052:Acanthosis Nigricans / Q000150:complications* / Q000188:drug therapy / Q000628:therapy; D000293:Adolescent; D000324:Adrenocorticotropic Hormone / Q000097:blood; D000735:Androstenedione / Q000097:blood; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008656:Mestranol / Q000627:therapeutic use; D009640:Norethindrone / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000150:complications* / Q000601:surgery; D011085:Polycystic Ovary Syndrome / Q000150:complications* / Q000601:surgery; D013739:Testosterone / Q000097:blood; D013798:Thecoma / Q000150:complications* / Q000601:surgery
D015068:17-Ketosteroids; D006063:Chorionic Gonadotropin; D013739:Testosterone; D000735:Androstenedione; D004997:Ethinyl Estradiol; D003907:Dexamethasone; D000324:Adrenocorticotropic Hormone; D007986:Luteinizing Hormone; D008656:Mestranol; D009640:Norethindrone